Drugs / QL1203
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07829588 | Nov 2026 → Feb 2028 expected | colorectal cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04234594 | Oct 2019 → Sep 2020 | — | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06949761 | Jun 2025 → Sep 2026 overdue | neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04233151 | Jan 2020 → Dec 2024 | colorectal cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL1203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07829588 ↗ |
| Modality | Monoclonal antibody | “a recombinant anti-EGFR fully human monoclonal antibody injection” NCT06949761 ↗ |
| Route | Intravenous | “6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle” NCT04233151 ↗ |
| Target | EGFR | “anti-EGFR” NCT06949761 ↗ |